Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design.
Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design.
复制标题
DOI：
10.1016/j.dadm.2017.01.003
复制
发表时间：
2017-01-01
期刊：
影响因子：
--
通讯作者：
van der Flier, Wiesje M
中科院分区：
文献类型：
--
作者：
de Wilde, Arno;van Maurik, Ingrid S;van der Flier, Wiesje M
简介：阿尔茨海默氏症生物标志物在日常实践（ABIDE）项目的目的是翻译知识的诊断测试（磁共振成像[MRI]、脑脊液[CSF]和淀粉样蛋白正电子发射断层扫描[PET]）应用于日常临床实践，重点关注轻度认知障碍（MCI）。ABIDE是一个为期3年的项目，采用多方面的设计，并使用定量和定性研究方法构建成相互关联的子研究。基于回顾性数据，我们为MCI患者制定了个性化的风险评估。首先，我们收集了来自当地记忆诊所的200名患者的MRI和CSF数据，以及来自三级医院的500名患者的淀粉样蛋白PET数据，以优化这些测试在日常实践中的应用。此外，ABIDE将制定最佳的患者-临床医生conversation.Discussion的战略：最终，这将导致一套实用的工具，为临床医生支持诊断测试的选择，并促进其结果的解释和沟通。
INTRODUCTION: The Alzheimer's biomarkers in daily practice (ABIDE) project is designed to translate knowledge on diagnostic tests (magnetic resonance imaging [MRI], cerebrospinal fluid [CSF], and amyloid positron emission tomography [PET]) to daily clinical practice with a focus on mild cognitive impairment (MCI).METHODS: ABIDE is a 3-year project with a multifaceted design and is structured into interconnected substudies using both quantitative and qualitative research methods.RESULTS: Based on retrospective data, we develop personalized risk estimates for MCI patients. Prospectively, we collect MRI and CSF data from 200 patients from local memory clinics and amyloid PET from 500 patients in a tertiary setting, to optimize application of these tests in daily practice. Furthermore, ABIDE will develop strategies for optimal patient-clinician conversations.DISCUSSION: Ultimately, this will result in a set of practical tools for clinicians to support the choice of diagnostic tests and facilitate the interpretation and communication of their results.